Voyager Therapeutics: Strong Financial Position and Promising Pipeline Justify Buy Rating
I'm PortAI, I can summarize articles.
TD Cowen analyst Phil Nadeau has maintained a Buy rating on Voyager Therapeutics (VYGR) stock, citing the company's strong financial position with $229 million in cash, ensuring operations until 2028. The promising Alzheimer’s pipeline, including assets VY7523 and VY1706, is progressing towards key milestones in 2026. Collaborations with Neurocrine Biosciences also indicate growth potential. Leerink Partners echoed this sentiment with a Buy rating and a $11.00 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments